Development of a Novel Vaccine Against HIV/AIDS

$0U19FY2002AINIH

National Center/Aids/Std Control/Prevent, Beijing

Investigators

Linked publications, trials & patents

Paper 33166321 Paper 32365354 Paper 30226172 Paper 30125283 Paper 30015611 Paper 29925664 Paper 29323268 Paper 29260681 Paper 28804168 Paper 28583578 Paper 28461151 Paper 28098531 Paper 28000753 Paper 27211899 Paper 27191934 Paper 27067056 Paper 26982379 Paper 26885816 Paper 26881418 Paper 26654122 Paper 26635249 Paper 26435189 Paper 26409239 Paper 26367002 Paper 26255890 Paper 25957327 Paper 25940354 Paper 25849828 Paper 25551435 Paper 25523971 Paper 25340354 Paper 25091477 Paper 25076186 Paper 24937647 Paper 24885692 Paper 24778414 Paper 24488975 Paper 24358269 Paper 24348203 Paper 24183056 Paper 24114445 Paper 23970745 Paper 23967241 Paper 23803488 Paper 23803487 Paper 23798720 Paper 23555616 Paper 23104743 Paper 23064531 Paper 23033525 Paper 22561314 Paper 22515989 Paper 22283377 Paper 21976646 Paper 21895680 Paper 21795672 Paper 21784304 Paper 21744000 Paper 21625486 Paper 21402453 Paper 21311745 Paper 21241494 Paper 21220768 Paper 21073767 Paper 20923686 Paper 20876641 Paper 20871629 Paper 20838364 Paper 20807451 Paper 20615260 Paper 20390487 Paper 20298490 Paper 20104111 Paper 20102792 Paper 20092794 Paper 19955560 Paper 19884910 Paper 19859027 Paper 19802744 Paper 19730110 Paper 19687041 Paper 19601780 Paper 19471870 Paper 19455077 Paper 19416076 Paper 19388846 Paper 19158150 Paper 19083267 Paper 18837413 Paper 18778963 Paper 18725558 Paper 18718801 Paper 18567448 Paper 18472194 Paper 18419457 Paper 18400288 Paper 18354344 Paper 18272760 Paper 18260799 Trial NCT00068991

Abstract

HIV infection in China has been increasing rapidly since 1995 and the infected people may reach 10 million by year 2010. An effective vaccine is our best hope to prevent and control the spread of HIV infection and AIDS. The major goal of this project is trying to get the novel recombinant HIV/AIDS vaccine which could efficiently eliminate the HIV infection and possibly supply a cross protection against the infection with different HIV subtypes. We hypothesize that a successful HIV/AIDS vaccine may mainly depend on its ability on induction of efficiently protective CTLs to abort the virus replication at the early stage before the viruses are completely assembled, and the neutralization antibodies are needed to help the CTLS effectively to play their roles through decreasing the virus load. To develop a novel HIV/AIDS vaccine, this application proposes to use a unique non-replicated vaccinia vector NTV derived from vaccinia virus Tiantan vector NTV derived from vaccinia virus strain, a genetically detoxified anthrax lethal toxin (Gdalt) and a replicable DNA vaccine vector (rDNA) in optimal combination to stimulate both efficient cellular and humoral immune responses against HIV/AIDS. We have made the following specific aims to reach the goal: 1. Constructing three classes of HIV-1 vaccine candidates based on NTV, Gdalt, and rDNA vector using HIV-1 antigens of Chinese origin. Selecting the early genes such as pol, nef, tat, rev and middle late gene gag to induce efficient CTLs and the env gene, gp160, to elicit neutralizing antibody; 2. Optimizing the combined immunization protocols of the vaccine candidates in animals; 3. Developing the vaccine candidates through process of pilot productions and pre-clinical toxicology tests, thus obtaining SDS approval; 4. Preparation for Phase I and II human trials. In this project, all the selected genes will match with the epidemic strain investigated in this CIPRA program. And the human trials will be carried out in the area of cohort studies (the research project 1-3 in this CIPRA program and the undergoing HPTN or NIH). The achievements of the specific aims in this project will not only contribute to the development of HIV/AIDS vaccine in China but also be benefit to the prevention and control of HIV/AIDS in other countries.

View original record on NIH RePORTER →